CG Oncology, Inc. Common stock
Symbol: CGON (NASDAQ)
33.36
▼ (-0.82%) -0.275
Company Description:
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Key Stats
- Today's Open: $33.35
- Today's High: $34.595
- Today's Low: $32.4
- Today's Volume: 2.41M
- Yesterday Close: $33.63
- Yesterday High: $34.735
- Yesterday Low: $32.5
- Yesterday Volume: 1.11M
- Last Min Volume: 352
- Last Min High: $33.355
- Last Min Low: $33.35
- Last Min VWAP: $33.35354
Company Profile
- Name: CG Oncology, Inc. Common stock
- Website: https://www.cgoncology.com
- Listed Date: 2024-01-25
- Location: IRVINE, CA
- Market Status: Active
- CIK Number: 0001991792
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $2.56B
- Round Lot: 100
- Outstanding Shares: 76.25M
- Asset Type: CS
RECENT FILINGS FOR CGON
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-09 | 8-K | View |
| 2025-09-08 | 4 | View |
| 2025-09-05 | 144 | View |
| 2025-09-05 | 8-K | View |
| 2025-09-04 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-03 | 144 | View |
| 2025-09-03 | 144 | View |
| 2025-08-08 | 10-Q | View |
| 2025-08-08 | 8-K | View |
| 2025-08-06 | 3 | View |
| 2025-08-06 | SCHEDULE 13G | View |
| 2025-07-18 | 4 | View |
| 2025-07-17 | 144 | View |
| 2025-07-11 | 8-K | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
| 2025-06-06 | 4 | View |
Latest News on CGON